

FOR IMMEDIATE RELEASE

Warren Whitehead named Chairman of PlantForm Board of Directors

GUELPH, Ont., Oct. 16, 2013—PlantForm Corporation announced today that **Mr. Warren Whitehead** has been elected Chairman of the Board of Directors. Mr. Whitehead replaces Dr. Mark Goldberg, who served as Chairman since the company's inception in 2008. Dr. Goldberg will continue as a director on the board, and chair its audit committee.

"I am pleased to take on the responsibility of Chairman and look forward to working with the board and management to broaden the company's financing base to support the next stage of growth and development," said Mr. Whitehead. "On behalf of the Board of Directors, management and staff, I thank Mark for his leadership and contributions to PlantForm over the last five years, and look forward to his continuing involvement on the board."

Mr. Whitehead is a Certified Management Accountant with extensive experience in financial operations of pharmaceutical and biotechnology firms. He is the former CFO of Arius Research Inc., an oncology antibody company acquired by Roche in 2008. Mr. Whitehead also served as CFO of Labopharm Inc., from 2000 to 2006, where he led several rounds of financing, including a NASDAQ offering. As CFO of Resolution Pharmaceuticals Inc. from 1998 to 2000, he managed the company's sale to Bracco SpA. His experience also includes positions in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead has an MBA from the University of Windsor. He served as a director on PlantForm's board for four years prior to his appointment as Chairman, a consensus decision of the board.

"I'm pleased to welcome Warren to the role of Chairman," said Dr. Don Stewart, President and CEO. "Warren's leadership and expertise in international financing and markets will be an important asset as PlantForm works to secure the funding necessary to bring our first products to market. I would also like to thank Mark for his dedication and leadership as Chairman over the past five years, and for continuing to support our growth as a director of the company."

Dr. Goldberg, a company founder, welcomed Mr. Whitehead and thanked the board and the management team for their support during his term as Chairman. "PlantForm has evolved rapidly and it's gratifying to see the company gaining momentum as it readies for market entry."

PlantForm Corporation was formed in 2008 to commercialize a plant-based manufacturing platform developed at the University of Guelph for low-cost monoclonal antibodies, protein drugs and vaccines that target cancer and other critical illnesses. The company is preparing to advance into the regulatory approval process for its first antibody product, a biosimilar version of the breast cancer drug Herceptin[®] (trastuzumab). Two additional biosimilar antibody drugs for cancer are in development, as are antibodies





plantformcorp.com

for the treatment of human immunodeficiency virus. Research is also under way on an enzyme to protect against nerve agent exposure, funded by the U.S. Defense Advanced Research Projects Agency. Projected revenue is more than \$120 million by 2017.

-30-

For more information, please contact:

Stacey Curry Gunn
Director of Communications
stacey.curry.gunn@plantformcorp.com
(519) 827-1131